CM
PRTK

Crestline Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Crestline Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-71,799
Closed -$1.73M – 179
2017
Q2 		$1.73M Buy
+71,799
New +$1.59M 0.23% 50

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Crestline Management's PRTK Position: Q3 2017 in Review

Crestline Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 71,799 shares — an estimated $1.73M sold.

Crestline Management first reported a position in PRTK in Q2 2017 and held it in 1 quarter. The position peaked at $1.73M in Q2 2017. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

  • Crestline Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 71,799 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.73M.
  • Crestline Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Crestline Management's Paratek Pharmaceuticals, Inc. position peaked at $1.73M in Q2 2017.
  • 133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.